Guided by data, Mosaic licenses two cancer compounds from Astex

Title

Mosaic Therapeutics Licenses Two Clinical-Stage Cancer Compounds from Astex to Advance Data-Driven Combination Therapies

Mosaic Therapeutics, a Cambridge, UK-based oncology company, has in-licensed two clinical-stage cancer compounds from Astex Pharmaceuticals, namely ASTX029 (an ERK1/2 inhibitor) and ASTX295 (an MDM2 antagonist)2 3.
ASTX029 has completed Phase 2 clinical trials, while ASTX295 has completed Phase 1 trials2.
Both compounds were studied in more than 100 patients each, exhibiting differentiated safety profiles and single-agent activity, supporting their further development in combination regimens2.
Mosaic plans to use its proprietary platform to identify and develop synergistic drug combinations tailored to biomarker-defined patient populations, aiming for greater efficacy and lasting response than monotherapy2 5.
The agreement grants Mosaic exclusive development rights for these compounds in combination products targeting patient groups with limited or no current treatment options2.
As part of the deal, Astex has taken a 19% equity stake in Mosaic upfront, with the potential to increase to 22% based on clinical milestones, and will receive future revenue shares2.
Astex’s CEO, Dr. Harren Jhoti, will join the Mosaic Board as an observer, further consolidating the collaboration between the two companies2.
The development strategy focuses on seeking broad, biomarker-driven indications across multiple tumor types2 5.